CNS Pharma Q1 net loss $3.5M; Berubicin GBM trial topline data H1 2025

CNS Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.41

Net loss $3.5M for Q1 2024, vs $4.9M in Q1 2023; R&D expense down to $2.4M from $3.6M.
Cash at March 31, 2024 was ~$0.8M; no revenue reported.
Enrollment completed in potentially pivotal Berubicin trial for GBM; DSMB recommended continuation in Dec 2023.
Topline data from Berubicin study expected first half 2025.
FDA granted Fast Track and Orphan Drug designations for Berubicin.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CNS Pharmaceuticals, Inc. reported the first quarter 2024 ended March 31, 2024 results: net income approximately $3.5 million, EPS $(0.34) per diluted share.

Period: the first quarter 2024 ended March 31, 2024
Net income: approximately $3.5 million
EPS: $(0.34) per diluted share
Result: reported results

Exact text from the filing

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter 2024 ended March 31, 2024.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

CNS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-003550

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.